Soleno Therapeutics Reports Strong Q4 Earnings, Exceeds Expectations

Soleno Therapeutics' stock fell 8.78% as it crossed below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.68% and S&P 500 down 1.01%.

Despite the stock's decline, Soleno Therapeutics reported a Q4 GAAP EPS of $0.80, exceeding expectations by $0.09, and a revenue of $91.73 million, surpassing forecasts by $3.18 million. This strong financial performance indicates sustained improvement in profitability and boosts investor confidence, even amid a challenging market environment.

The company's robust cash flow and optimistic market outlook, including plans for EU regulatory approval and capturing new patient start forms, suggest a positive trajectory for future growth. Investors may view this earnings report as a strong foundation for Soleno's ongoing market expansion.